Drugs / JANX007
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05519449 | Sep 2022 → Jul 2027 expected | castration-resistant prostate carcinoma | Janux Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JANX007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05519449 ↗ |
| Route | Intravenous | “JANX007 is dosed via IV” NCT05519449 ↗ |